BioScrip Inc. (NASDAQ:BIOS)’s share price was up 2.7% on Thursday . The stock traded as high as $2.67 and last traded at $2.65, with a volume of 450,016 shares changing hands. The stock had previously closed at $2.58.

Separately, Zacks Investment Research upgraded shares of BioScrip from a “hold” rating to a “buy” rating and set a $3.00 price objective on the stock in a report on Monday.

The firm’s market cap is $180.89 million. The firm’s 50-day moving average is $2.63 and its 200 day moving average is $2.23.

BioScrip (NASDAQ:BIOS) last issued its quarterly earnings data on Thursday, May 5th. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by $0.05. The company earned $238.50 million during the quarter, compared to analysts’ expectations of $232.38 million. BioScrip’s revenue was down 2.4% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.17) EPS. Equities research analysts predict that BioScrip Inc. will post ($0.20) EPS for the current fiscal year.

In related news, Director Coliseum Capital Management, L acquired 4,200,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 22nd. The stock was purchased at an average cost of $2.00 per share, for a total transaction of $8,400,000.00. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director David W. Golding acquired 12,500 shares of the firm’s stock in a transaction that occurred on Friday, June 17th. The shares were bought at an average price of $2.48 per share, with a total value of $31,000.00. Following the completion of the purchase, the director now directly owns 42,500 shares in the company, valued at $105,400. The disclosure for this purchase can be found here.

Other large investors have added to or reduced their stakes in the company. Diamond Hill Capital Management Inc. boosted its stake in BioScrip by 2.5% in the fourth quarter. Diamond Hill Capital Management Inc. now owns 3,055,476 shares of the company’s stock worth $5,347,000 after buying an additional 74,757 shares during the period. Gabelli Funds LLC boosted its stake in BioScrip by 22.9% in the fourth quarter. Gabelli Funds LLC now owns 11,430,900 shares of the company’s stock worth $20,004,000 after buying an additional 2,132,060 shares during the period. Finally, Gamco Investors INC. ET AL boosted its stake in BioScrip by 1.4% in the fourth quarter. Gamco Investors INC. ET AL now owns 864,850 shares of the company’s stock worth $1,513,000 after buying an additional 12,250 shares during the period.

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.